Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Details)

v3.20.1
SEGMENT INFORMATION (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2020
USD ($)
segment
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Segment Reporting Information [Line Items]      
Number of operating segments | segment 2    
Product sales, net $ 8,270 $ 14,911  
Gross profit 4,008 10,559  
Research and development 1,509 1,342  
Selling, general and administrative 7,819 18,595  
Operating Loss (5,320) (9,378)  
Goodwill 2,788   $ 2,788
Intangible assets 3,757   3,766
Consumer Products Segment      
Segment Reporting Information [Line Items]      
Product sales, net 8,270 14,911  
Gross profit 4,008 10,559  
Research and development 305 699  
Selling, general and administrative 7,810 18,585  
Operating Loss (4,107) (8,725)  
Specialty Pharmaceutical Segment      
Segment Reporting Information [Line Items]      
Product sales, net 0 0  
Gross profit 0 0  
Research and development 1,204 643  
Selling, general and administrative 9 10  
Operating Loss (1,213) $ (653)  
Goodwill 2,800   2,800
Intangible assets $ 3,800   $ 3,800